Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients

Bocchio-Chiavetto, Luisella; Zanardini, Roberta; Bortolomasi, Marco; Abate, Maria; Segala, Matilde; Giacopuzzi, M.; Riva, Marco A.; Marchina, Eleonora; Pasqualetti, Patrizio; Pérez, Jorge; Gennarelli, Massimo

doi:10.1016/j.euroneuro.2006.04.010

Cited by 159 publications

(99 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because BDNF affects cell growth and survival and is expressed in the CNS 3) , the effects of BDNF on neuroplasticity after ECT would extend for some duration in depressive patients. A previous study also reported a progressive elevation of serum BDNF levels for 1 month following ECT, and it has been suggested that a progressive elevation of serum BDNF levels might represent the consequence of the adaptive process in depressed patients, such as a change of neuro-hormonal and psychoimmune systems, and alterations of platelets function 7) . There might be a possibility that such adaptive processes relate to progressive increase of serum BDNF levels following ECT.…”

Section: Discussionmentioning

confidence: 99%

“…Using the same three measurement times applied during the study period, Piccinni et al 12) and Bocchio-Chiavetto et al 7) reported that BDNF levels increased progressively following ECT, and the changes in BDNF levels following ECT have been suggested to be time-related 12) . Peripheral BDNF levels might take relatively longer to increase compared to the rapid effects of ECT 19) .…”

Section: Discussionmentioning

confidence: 99%

“…Accordingly, BDNF activity in the CNS has been considered to represent neurophysiological changes associated with recovery of depression 3), 6) . Studies have measured peripheral (i.e., serum or plasma) levels of BDNF before and after ECT in depressive patients [7][8][9][10][11][12][13][14][15][16][17][18] . A recent meta-analysis by Brunon 19) found a significant increase in peripheral BDNF levels after ECT in depressive patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum Brain-derived Neurotrophic Factor Levels Following Electroconvulsive Therapy in Treatment-resistant Depressed Patients

Sasaki

Kamata

Higuchi

et al. 2015

J St. Marianna Univ

View full text Add to dashboard Cite

Objectives: To determine whether serum levels of brain-derived neurotrophic factor (BDNF) are associated with response to electroconvulsive therapy (ECT) in treatment-resistant depressed patients with a relatively longer period of measurement. Methods: This study included 30 Japanese unipolar depressed patients with current major depressive episode. Montgomery-Äsberg Depression Rating Scale (MADRS) score was ≥21 in all subjects. ECT was performed twice a week for a total of 4-10 sessions. Serum BDNF levels were measured before ECT (T0), the day after the last ECT session (T1), and 1 month after the last ECT session (T2). Patient response to treatment was defined as a ≥50% decrease compared with the pretreatment total MADRS score. Results: Serum BDNF levels showed no significant variation among the patients during the entire study period. In responders, serum BDNF levels showed a progressive increase, and the differences between T0 and T1 and between T0 and T2 were significant (p=0.022 and p=0.007, respectively). In non-responders, serum BDNF levels showed a progressive decrease, and the difference between T0 and T2 was significant (p=0.012). No significant association was identified between change in serum BDNF level and change in total MADRS score in any of the patients following ECT. Conclusions:The present results showed that serum BDNF levels after ECT increased progressively in responders, but not in non-responders. Our results provide important information for understanding the exact role of BDNF in the antidepressive effects of ECT.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Brain-derived Neurotrophic Factor Levels Following Electroconvulsive Therapy in Treatment-resistant Depressed Patients

Sasaki

Kamata

Higuchi

et al. 2015

J St. Marianna Univ

View full text Add to dashboard Cite

show abstract

“…32 Other studies did not find significant changes in serum levels of BDNF in depressed patients submitted to ECT. 33,34 ECT and quality of life Studies showed that ECT, besides improving the patients' symptoms, also improves their QOL.…”

Section: Ect and Remission Of Symptomsmentioning

confidence: 98%

Eletroconvulsoterapia na depressão maior: aspectos atuais

Antunes

Rosa

Belmonte-de-Abreu

et al. 2009

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

“…There is some clinical evidence pointing to a positive correlation between levels of BDNF and anti-depressive treatment response (Shimizu et al 2003, Bocchio-Chiavetto et al 2006, Marano et al 2007, Machado-Vieira et al 2009, Piccinni et al 2009). …”

Section: The Neuroplasticity Hypothesis In Anti-depressive Treatmentmentioning

confidence: 99%

On electroconvulsive therapy in depression : Clinical, cognitive and neurobiological aspects

Nordanskog¹

2015

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) is used worldwide to treat severe mental disorders. The most common mental disorder, and the third leading cause of disease burden in the world is depression. The clinical efficacy of ECT for severe depression is well-established. However, both the pathophysiology of depression and the mechanism of action of ECT remain elusive. The main aims of this thesis are to address the following issues: 1) the use and practice of ECT in Sweden has not been systematically evaluated since 1975, 2) cognitive side-effects (memory disturbances) are a major concern with ECT and 3) the mechanism of action of ECT remain elusive. The neurobiological aspects of ECT focus on two hypotheses. First, the recent years´ preclinical studies that have provided evidence that ECT induces hippocampal cell proliferation, including neurogenesis. Second, that enhanced functional inhibition of neuronal activity is a key feature. Current use and practice of ECT in Sweden (paper I) is based on data from the national quality register for ECT, the mandatory patient register of the National Board of Health and Welfare and a survey. Treated person rate (TPR) in Sweden 2013 was found to be 41 individuals / 100 000, and thus unchanged since the latest systematic investigation in Sweden 1975. In more than 70% of treatment series the indication was a depressive episode. The selection of patients for ECT and treatment technique in Sweden was similar to that in other western countries, but the consent procedure and the involvement of nurses and nursing assistants in the delivery of ECT differ. Data also shows that there is room for improvement in both the specificity of use and availability of ECT. The second study in this thesis is a longitudinal observational trial where 12 (paper II and III) and 14 (paper IV) patients with depression referred for ECT were investigated. Patients underwent a 3 T MRI structural scanning and DSC-MRI perfusion, a neuropsychological test battery and clinical ratings before ECT, within one to two weeks after ECT and after 6 and 12 months. In line with preclinical findings and the plasticity hypothesis of mechanism of action of ECT, the hippocampal volume increased after ECT in patients with depression. However, this increase was transient and returned to baseline levels within 6 months. No correlation was found between volumetric changes and clinical effect or cognitive outcome. Instead our results suggested an association to the number of treatments, without relation to the side of stimulation. A right-sided decrease in frontal blood flow distinguished remission from non-remission after ECT. There were significant impairments in verbal episodic memory and verbal fluency within one week after ending the ECT course, but these impairments were transient and no persistent cognitive impairments were seen during the follow-up. In summary, this thesis present the first update on the use and practice of ECT in Sweden in the last 40 years as well as a pioneering MRI-study on the hippocampal volume increase...

show abstract

Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients

Cited by 159 publications

References 42 publications

Serum Brain-derived Neurotrophic Factor Levels Following Electroconvulsive Therapy in Treatment-resistant Depressed Patients

Serum Brain-derived Neurotrophic Factor Levels Following Electroconvulsive Therapy in Treatment-resistant Depressed Patients

Eletroconvulsoterapia na depressão maior: aspectos atuais

On electroconvulsive therapy in depression : Clinical, cognitive and neurobiological aspects

Contact Info

Product

Resources

About